Nico Vandervelpen

SEPS Pharma NV provides controlled drug delivery and develops self emulsifying pro drug systems. Its services include preformulation, formulation development and analytical development. The company was founded on October 19, 2007 and is headquartered in Diepenbeek, Belgium.

Ernst & Young provides accounting services. Its services include auditing, accounting, tax and transaction services, assurance and advisory business, online transaction advisory and a wide range of financial services. The company was founded by Arthur Young and Alwin C. Ernst in 1881 and is headquartered in Kansas City, MO.

Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium.

MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine.

Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium.

Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.

Limburgse Reconversie Maatschappij NV (LRM) is an independent private equity firm which was founded in 1994 by the Flemish government. Limburgse Reconversie Maatschappij NV is headquartered in Hasselt, Beglium.

Life Sciences Development Campus NV provides research and development services in the field of biomedical life sciences. The company is headquartered in Abis, BelGium.